These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30476873)

  • 1. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.
    Eskyte I; Manzano A; Pepper G; Pavitt S; Ford H; Bekker H; Chataway J; Schmierer K; Meads D; Webb E; Potrata B
    Mult Scler Relat Disord; 2019 Jan; 27():370-377. PubMed ID: 30476873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
    Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
    J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA.
    Brown H; Gabriele S; White J
    Neurodegener Dis Manag; 2018 Dec; 8(6):371-376. PubMed ID: 30451064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.
    Manzano A; Eskytė I; Ford HL; Bekker HL; Potrata B; Chataway J; Schmierer K; Pepper G; Meads D; Webb EJ; Pavitt SH
    Patient Educ Couns; 2020 May; ():. PubMed ID: 32456983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
    Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
    BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).
    Ceuninck van Capelle A; Meide HV; Vosman FJH; Visser LH
    PLoS One; 2017; 12(8):e0182806. PubMed ID: 28837609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
    Reyes S; Suarez S; Allen-Philbey K; Yildiz Ö; Mathews J; Anjorin G; Edwards F; Jain C; Turner B; Marta M; Gnanapavan S; Schmierer K; Giovannoni G
    Mult Scler Relat Disord; 2020 Jun; 41():102024. PubMed ID: 32143179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
    Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
    Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
    Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R
    Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.
    Young CA; Rog DJ; Sharrack B; Tanasescu R; Kalra S; Harrower T; Tennant A; Mills RJ;
    Neurol Sci; 2024 May; 45(5):2181-2189. PubMed ID: 37976012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study.
    Cameron E; Rog D; McDonnell G; Overell J; Pearson O; French DP
    Mult Scler Relat Disord; 2019 Jan; 27():378-382. PubMed ID: 30500689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.
    Burtchell J; Clemmons D; Clemmons J; Sabutis T; Rosenberg A; Graves J; Sweeney ML; Kramer J; Ziehn M; Brown B; Weiss JL; Obeidat AZ
    Neurol Ther; 2022 Sep; 11(3):955-979. PubMed ID: 35608740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: item response theory modelling and confirmatory factor analysis.
    Ballesteros J; Moral E; Brieva L; Ruiz-Beato E; Prefasi D; Maurino J
    Health Qual Life Outcomes; 2017 Apr; 15(1):79. PubMed ID: 28431587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best Methods of Communicating Clinical Trial Data to Improve Understanding of Treatments for Patients with Multiple Sclerosis.
    Reen GK; Silber E; Langdon DW
    Value Health; 2018 Jul; 21(7):762-766. PubMed ID: 30005747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol.
    Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Evers S; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Lemmens WA; Donders R; van der Zande A; Visser LH
    BMC Neurol; 2016 May; 16():81. PubMed ID: 27234001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.